# CBD, Medicare, and the New FDA Enforcement Memo – Canna Law Blog™ > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medicare-coverage-cbd-products-fda-enforcement-memo/ > **Published:** 2026-04-03T19:03:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T14:02:42-04:00 > **Clinical Summary:** Explore Medicare coverage CBD products and the impact of the new FDA enforcement memo on patient access and clinical compliance. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic CbdMedicareFdaPolicyAccess Why This Matters Medicare coverage decisions and FDA enforcement policies directly impact patient access to [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) and create legal uncertainty for clinicians considering cannabis recommendations. Understanding these regulatory boundaries is essential for providing compliant [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) while navigating coverage limitations. Clinical Summary The FDA’s enforcement memorandum clarifies regulatory boundaries around [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) and Medicare coverage, though specific details of policy changes are not provided in the source material. Medicare typically does not cover non-FDA approved cannabis products, creating access barriers for patients who might benefit from CBD therapy. These regulatory frameworks continue to evolve as federal agencies balance enforcement priorities with growing clinical interest in cannabinoid therapeutics. Dr. Caplan’s Take “Without clear federal pathways, patients often face significant out-of-pocket costs for CBD products that might provide clinical benefit. I counsel patients that regulatory uncertainty doesn’t negate potential therapeutic value, but it does mean navigating a complex landscape of coverage and compliance.” Clinical Perspective 🧠 Clinicians should stay informed about evolving FDA guidance and Medicare policies to provide accurate coverage expectations to patients. Document clinical rationale for CBD recommendations thoroughly, and help patients understand that most CBD products remain patient-pay rather than insurance-covered therapies. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20CBD%2C%20Medicare%2C%20and%20the%20New%20FDA%20Enforcement%20Memo%20-%20Canna%20Law%20Blog%E2%84%A2%20%40drcaplan&url=https%3A//harris-sliwoski.com/cannalawblog/cbd-medicare-and-the-new-fda-enforcement-memo/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//harris-sliwoski.com/cannalawblog/cbd-medicare-and-the-new-fda-enforcement-memo/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20CBD%2C%20Medicare%2C%20and%20the%20New%20FDA%20Enforcement%20Memo%20-%20Canna%20Law%20Blog%E2%84%A2%20--%20via%20%40drcaplan.bsky.social%20https%3A//harris-sliwoski.com/cannalawblog/cbd-medicare-and-the-new-fda-enforcement-memo/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://harris-sliwoski.com/cannalawblog/cbd-medicare-and-the-new-fda-enforcement-memo/](https://harris-sliwoski.com/cannalawblog/cbd-medicare-and-the-new-fda-enforcement-memo/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What topics does this article cover?](#What_topics_does_this_article_cover) - [Why is this considered “emerging” information?](#Why_is_this_considered_8220emerging8221_information) - [How does this relate to clinical practice?](#How_does_this_relate_to_clinical_practice) - [What should healthcare professionals do with this information?](#What_should_healthcare_professionals_do_with_this_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What topics does this article cover? The article focuses on CBD, Medicare coverage, FDA regulations, and [healthcare policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/) developments. These interconnected topics suggest coverage of regulatory changes affecting patient access to CBD treatments. #### Why is this considered “emerging” information? The article is marked as “New” and classified under emerging findings or policy developments. This indicates recent developments in the intersection of [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), federal healthcare programs, and regulatory oversight. #### How does this relate to clinical practice? As a CED Clinic publication focusing on cannabis news, this information is particularly relevant for healthcare providers treating patients with [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). The Medicare and FDA aspects suggest implications for patient coverage and treatment protocols. #### What should healthcare professionals do with this information? Given the “Notable Clinical Interest” rating, healthcare professionals should monitor these developments closely. The policy implications may affect patient access to CBD treatments and reimbursement through Medicare programs. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [CMS Finalizes CY 2027 Medicare Advantage and Part D Rule | Insights | Holland & Knight](https://cedclinic.com/medicare-advantage-payment-rate-increase-2027/) Detailed insights on the latest Medicare Advantage and Part D rules finalized for 2027, impacting coverage policies. [Read More](https://cedclinic.com/medicare-advantage-payment-rate-increase-2027/) [Commercial Insurance Has Failed Cannabis. Here's What's Next](https://cedclinic.com/cannabis-insurance-coverage-gaps-whats-next/) Explore the challenges and future directions of commercial insurance in the cannabis industry. [Discover More](https://cedclinic.com/cannabis-insurance-coverage-gaps-whats-next/) Beyond Licensing: The New Face Of Fintech Compliance Under The NDPA, GAID And CBN … An overview of evolving fintech compliance frameworks relevant to cannabis businesses and regulatory landscapes. Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).